7-溴-1-甲基-3,4-二氢-2(1H)-喹啉酮 | 1086386-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-溴-1-甲基-3,4-二氢-2(1H)-喹啉酮
• 英文名称: 7-bromo-1-methyl-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 7-bromo-1-methyl-3,4-dihydroquinolin-2-one
• CAS: 1086386-20-0
• 化学式: C₁₀H₁₀BrNO
• 分子量: 240.099
• InChiKey: XVBPEXCFWANWIM-UHFFFAOYSA-N

物化性质

• 熔点：
  130-134℃
• 沸点：
  414.7±45.0 °C(Predicted)
• 密度：
  1.500±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-溴-1-甲基-3,4-二氢-2(1H)-喹啉酮 、 7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydroquinoline 在 dichloro(1,3-bis(2,6-bis(3-pentyl)phenyl)imidazolin-2-ylidene)(3-chloropyridyl)palladium(II) 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以41%的产率得到7-[7-(difluoromethyl)-6-(1-methylpyrazol-4-yl)-3,4-dihydro-2H-quinolin-1-yl]-1-methyl-3,4-dihydroquinolin-2-one
  参考文献：
  名称：

  A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors

  摘要：

  The epigenetic regulator CBP/P300 presents a novel therapeutic target for oncology. Previously, we disclosed the development of potent and selective CBP bromodomain inhibitors by first identifying pharmacophores that bind the KAc region and then building into the LPF shelf. Herein, we report the "hybridization" of a variety of KAc-binding fragments with a tetrahydroquinoline scaffold that makes optimal interactions with the LPF shelf, imparting enhanced potency and selectivity to the hybridized ligand. To demonstrate the utility of our hybridization approach, two analogues containing unique Asn binders and the optimized tetrahydroquinoline moiety were rapidly optimized to yield single-digit nanomolar inhibitors of CBP with exquisite selectivity over BRD4(1) and the broader bromodomain family.

  DOI：

  10.1021/acs.jmedchem.7b01372

文献信息

• IMIDAZOPYRAZINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20160009720A1

  公开（公告）日：2016-01-14

  The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及咪唑并[1,2-a]吡嗪衍生物，这些衍生物是LSD1抑制剂，可用于治疗癌症等疾病。
• Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
  申请人：Incyte Corporation

  公开号：US10112950B2

  公开（公告）日：2018-10-30

  The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及式 I 的咪唑并[1,2-a]吡嗪衍生物或其药学上可接受的盐，它们是治疗癌症等疾病的 LSD1 抑制剂。
• US9695180B2
  申请人：——

  公开号：US9695180B2

  公开（公告）日：2017-07-04
• [EN] IMIDAZOPYRAZINES AS LSD1 INHIBITORS<br/>[FR] IMIDAZOPYRAZINES EN TANT QU'INHIBITEURS DE LSD1
  申请人：INCYTE CORP

  公开号：WO2016007736A1

  公开（公告）日：2016-01-14

  The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.